In this double-blind, placebo-controlled. crossover. parallel study, we treate d 20 adults who had seasonal allergic rhinitis with once-dailyjixed-comb ination loratadine/ pseudo ephedrine sulfate to observe its effect on relie ving sympt oms. prima rily nasal congestion. Acoustic rhinometry detected a trend towa rd improvement in nasal patency. although the differe nce betwee n pre-and posttreatment measures was not statistically significant. Endoscopic inf erior turb inate photography documented that treatment led to statistica lly significant reductio ns in the amount ofnasal edema and nasal secre tions. The results ofa quality-of-!if e questionnaire suggested that treatment alleviated nasal and ocular symptoms of rhinoconjun ctivitis. An analysis ofsubjective visual anal og scale scores showed a trend toward improvement in most but not all nasal symptoms. We conclude that once-a-day fi xedcombination loratadine/pseudoephedrine is effec tive in relieving nasal congestion in pa tients with seasonal allergic rhinitis. -MCFADDEN, GUNGOR, NG, MAMIKOGLU, MOINUDDIN , COREY * Values for each measurem ent are the total f or both sides ofthe nose. t Ranges for nasal volume are measured in em'.
Introduction
Symptoms of seasonal allergic rhinitis inc lude nasal co nges tio n, rhin orrhea, nasal and th roat itching, postn asal dri p, and sneez ing. Of these five symptoms, nasa l conges- 254 tio n is the most frequ ent and often the most severe.!-' The phys ical signs assoc iated with seasonal allergic rhinit is are eryt hema of the nasa l mucosa, edema ofthe turbinates, and excessive nasal secre tions.
Th e corne rsto nes of treatm ent are antihis ta mines and decongestants. Th e sig ns and sy mptoms of allergic rhinitis are med iated pr imaril y by histamin e. Symptom s occ ur as a result of the dir ect and indirec t ac tions of histamin e on H I and, to a lesser ex tent, H l rece ptors.' Antihistamines, by blockin g HI recept ors, are effec tive in suppressing rhinorrh ea and sneezing, but they are less effecti ve in relieving nasal con gestion . Th e reason is that ant ihistamines cannot blunt the prolonged action of other vasoactive medi ators (kinins and leukotrienes), nor can they reverse capi llary vasodil ation , which is mediated by H, receptors.' Decongestants are alpha-adrenoceptor ago: nists that con strict the upp er respiratory mucosal vessels, thu s redu cing muc osal ede ma and lessenin g the subj ective sensa tion of nasal conges tion.
Loratadine is a non sed ating antihistamine that has been found to be safe and effective in reliev ing rhino rrhea, nasal itching, and sneezi ng in pat ient s wi th seasonal allerg ic rhinitis.' Pseud oeph edrine sulfate is an orally ac tive decongestant that reduces nasal ede ma and alleviates co nges tion. Th e o nce-dai ly fixed-combination form of these two drugs (Clariti n-D 24 Hour; Schering Corp.) co ntai ns 10 mg of imm ed iate-release loratadin e and 240 mg of extended-release pse udoe phedrine and has been app roved for the reli ef of sy mptoms of seasonal allergic rhi nitis. In a study by Bron sky et al, this fixe d-co mbination age nt was shown to be safe and effec tive in relieving ove rall nasal sy mpto ms, as well as the spec ific sy mptom of nasal conges tion."
Th e goal of this study was to further evaluate the efficacy ofl oratadine/pse udoe phedrine in relieving nasal ENT 
TOVENT .
congestion in patients with seasonal allergic rhinitis, and to assess by several different measures of effectiveness its effect on other common parameters associated with allergic rhinitis. These measures included an objective quantitative instrument (acoustic rhinometry), an objectivequalitati ve instrument (endoscopic inferior turbinate photography) , and two patient-oriented quantitative instruments (rhinoconjunctivitis quality-of-life questionnaire scores and visual analog allergic symptom scores).
Treatment for Negative
Pressure and Otitis To be eligible for this study, patients had to have been free from intranasal and parenteral steroids for 2 weeks , astemizole for at least 3 months , other antihistamines for at least 3 days , and decongestants and ipratropium for at least I week prior to starting the study. Seasonal allergic rhinitis to ragweed was diagnosed by a positive skin prick test or by an allergen-specific enzyme immunoassay (Pharmacia Diagnostics; Piscataway, N.J .) result of class 2 or greater."Patients had to have been free of other health problems, could not be taking alpha blockers, and they must not have had any contraindication to using pseudoephedrine. All patients were informed ofthe procedures, treatments, and potential risks they might encounter during the study, and all signed informed consent statements before their first visit. Patients were also instructed on how to complete the quality-of-life questionnaire and how to perform the visual analog test prior to starting the study .
During their initial visit to the allergy clinic, patients provided their medical history and underwent an otolaryngologic examination, with spec ific emphasis on the nasal examination. They also underwent allergy testing for specific weeds. Nasal congestion was measured objectively by two means: quantitatively by acoustic rhinometry and qualitatively by a blinded visual analysis of endoscopic color photography of the inferior turbinates. Symptoms of nasal congestion were quantified by rhinoconjunctivitis quality-of-life questionnaire scores and visual analog allergic symptom scores. The seven women in the study were tested for pregnancy, and all result s were negative. These women all agreed to practice birth control for the duration of the study , and they all had a negative urine pregnancy test immediately after the completion of the study.
All patients had to agree to spend at least I hour outdoors each day in an area of Chicago where natural Volume 79, Number 4 MCFADDEN. GUNGOR. NG. MAMIKOGLU. MOINUDDIN. COREY exposure to ragweed pollen was expected to occur. Depending on which group they had been randomized to, patients were instructed to take either the active drug or placebo once a day between 7 and 8 a.m.
Patients returned to the allergy clinic 7 days after their initial visit. Acoustic rhinometry and endoscopic photography were repeated, and quality-of-life and visual analog scores were again recorded. Patients were also questioned about any leftover medications. Following a washout period of at least 7 days, patients returned for a third visit, and the same procedures and tests were repeated. Patients were then crossed over to the alternate regimen for 7 days. After 1 week on the alternate regimen, they returned for the fourth and final visit, and the procedures and tests were again repeated; patients were also questioned again regarding any leftover medications, and the women underwent a second pregnancy test.
Treatment schedules were in part dependent on pollen counts in the Chicago area, which were recorded at the nearest American Academy of Allergy, Asthma, and Immunology testing station. When pollen counts were low, treatment for some patients was postponed and the washout period for others was extended. The aim was to have all patients on their regimen when counts were higher than 50.
Acoustic rhinometry. Acoustic rhinometry was performed with a second-generation rhinometer (Hood Laboratories; Pembroke, Mass.) according to the protocol established by Hilberg.' Each patient's nasal patency was evaluated by measuring the cross-sectional area (CSA) of the nose at the nasal valve (CSAI), at the anterior portion of the inferior turbinate (CSA2), and at the anterior portion of the middle turbinate (CSA3). We also measured the total nasal volume. Measurements were taken of both sides of the nose and considered together to minimize any possible influence of the nasal cycle. The greater the cross-sectional area and nasal volume, the less the nasal obstruction.
Endoscopic photography. To obtain endoscopic photographs of the inferior turbinates, we asked patients to sit in a hydraulic examining chair that was equipped with a stable head support to prevent excess head movement during the examination. The height of the chair was adjusted to bring the floor of the nasal fossa to the level of the Hopkins 4 mm 0" endoscope, which was connected to a video camera with a C-ring. The endoscope was placed MIRROTHERM PLUS P c I I-worsening of 0.006 (±0.246) em".
CSA2. Likewise, active treatment increased the mean CSA2 value by O. I I (±0.424) em", while placebo resulted in a mean worsening of 0.03 (±0.694) cm-.
CSA3. The mean CSA3 value improved during both active and placebo treatment-by 0.076 (±0.629) and 0.017 (±0.927) em", respectively.
Nasal volume. The mean nasal volume increased by 0.398 (±1.891) ern' during active treatment, and decreased during placebo treatment by O. I55 (±3.109) ern'.
Although the differences in these four measurements during active and placebo treatment were not statistically significant, they do indicate a positive trend.
Endoscopic photography. Two photographs of the inferior turbinate of each patient were evaluated for the amount of redness , edema, and secretions ( 
Volume at the anterior margin of the inferior turbinate, and the distance from the tip of the endoscope to the C-ring was measured. Two still photographs of each side of the nose (again, to minimize the influence of the nasal cycle) were obtained from the videotaped recording of the anterior nasal endoscopic examination. The photographs of the inferior turbinates were evaluated in a blinded fashion by two investigators for redness, edema, and secretions. Each of these parameters was rated on a scale of 0 (none) to 5 (severe). The total score at each visit was obtained by adding the grades of both observers for both photographs for both sides of the nose. The maximum score for each of the three parameters was 40.
Quality-of-life questionnaire. Our rhinoconjunctivitis quality-of-life questionnaire was based on that designed by Juniper and Guyatt."The questionnaire covers seven domains: nasal symptoms, eye symptoms, other symptoms, performance of daily activities, practical problems, quality of sleep, and emotional status. Patients rated themselves on a scale of I (hardly troubled) to 6 (extremely troubled).
Visual analog symptom scale. There were nine domains of nose and eye symptoms measured on the visual analog scale. The five nasal domains were stuffy nose (which was the focus of this study), runny nose, nasal or throat itching, postnasal drip, and sneezing. The four eye domains were itchy eyes, watery eyes, sore or red eyes, and swollen eyes. Patients rated the degree of their symptoms on a scale of 0 (none) to 100 (very severe) . Key to timing of measurements: BA =bef ore active treatment;AA =after active treatment; BA-AA = difference in measurements bef ore and afte r active treatment; BP = before placebo; AP = after placebo; BP-AP = difference in measurements before and after placebo.
p value p = 0.037 p = 0 .305 p= 0.856 p = 1.58 p = 0.466 p = 0 .007 the mean redness score improved by 1.00 (±6 .0) point ; during placebo treatment, the mean score decreased by 1. 10 (±4.07) points .
Edema. The mean edema score improved an average of 4.10 (±6.0) points during active treatme nt; the difference between the pre-and post-treatment scores was statistically significant (p<O.O 1). The mean edema score also improved slightly during placebo treatment (0.20 [±4.9]) , but the difference between pre-and posttreatment values was not statistically significant.
Secretions. Th e mean secretion score improved by a statis tically significan t 2.60 (±5 .I) point s (p<0 .04) during active treatment , and worsened by 2.10 (±6.2) points during placebo treatment.
Quality-of-life questionn aire. All 20 patie nts answered the quality-of-life surveys at each session (table 3) . Findings: Nasa l symptoms. T he difference in mean nasal symptom scores before and after loratadine /pseudoephedrine treatment was 0.60 (± 1.16) points . This difference wa s statistically significant (p<0 .04) and met Juniper et aI' s defin ition of a "minimally important difference " (MID :~0 .5) . 9 The difference in mea n nasa l symptom scores before and after placebo was only 0.07 (± 1.85) point s, which was neither clinically important nor statistically significant.
Eye symptoms. The pre-and post-treatment difference in mean eye symptom scores was 0.57 (± 1.32) point s during loratadine/pseudoephedrine therapy .This represented a clinically important improvement, and it approached, but did not reach, statistical significance (p<0 .08) . The difference before and after placebo treatment was 0.14 (± 1.31) points , which was not significant either clinically or statistically.
Other symptoms. The mean score for symptoms other than those involving the nose and eyes rose 0.18 (±0 .77) points after loratad ine/pseudoephedrine treatment, but the difference was not clinically important or statistically significant. The same was true of the difference during placebo treatment (0.13 [±1. 2"7] Practical problems. The mean score repre senting practical problems rose 0.47 (± 1.23) points after active treatment, a figure that was not statistically significant but was clinic ally important. The increase after placebo treatment Eye symptoms was 0.45 (± 1.42) points, which was not statistically significant but did approach clinical importance. p value Quality of sleep. The patients' quality of slee p appeared to worse n slightly after loratadine/pseudoephedrine treatm ent, as the p=0.070 mean sco re fell 0.12 (± 1.40) point s. However, this decrease was neith er clin icall y important nor statistically significa nt. Likep = 0.644 wise, the appare nt improvement in sleep after placebo (0.28 [±1.67]) was not clinip = 0.032 cally important or statistically significant.
Emotional status. The increase in the mean emotional status score after loratadine/pseup = 0.858 doephedrine treatm ent was 0.40 (±0.98), which approac hed both clinical importance and statistical significance (p<0 .09). There p = 0 .314 was virtually no difference in emotional status scores after placebo (-0.0 1 [±1.l6]).
Visual analog symptom scale. We anap = 0 .654 Iyzed five nasal symptoms (table 4) and four eye symptoms (table 5) as rated by each p = 0.227 patient on the visual analog sy mptom scale.
Findings : Nasal domains. The mean stuffy nose p = 0.764 score incr eased by 3.3 (±36. 53) point s after loratadine/p seud oephedrine treatment and decreased by 4.90 (±30.58) points after plap = 0.104 cebo. On the other hand , rhinorrh ea worsened follow ing activ e treatment , as the mean score decreased by 6.75 (±2 1.23) points; p = 0.1 74 dur ing placebo, the mean score incre ased by 6.25 (±3 1.85) points, but the differen ce between the study medication and placebo p = 0 .718 values was not significant. Th e mean score for nasal or throat itching impro ved slightly following active treatment ( With the addition of this latest sinuscope, our line is complete. And no one offers a clearer, broader vision of sinuscopes with ergonomic design for perfect balance between form and function . No one. 
Discussion
Our study foc used primarily on nasal congestion because it is often extremely bothersome . We used aco ustic rhino me try to measure nasal co ngestion because it has bee n found to be reliable in giving an objective assessment of nasal patency." Rhinometry Runny nose shows the cross-sectional area of the entire nasa l cavity and essentially pro vides a topographic map of the nose. Hilberg et al found that cross-sectional measurements on acoustic rhinometry are reliab le.' Rhinometry has a coefficient of variation ofless than 2%, and it provides a good correlation between act ual volume and total measured nasa l volume.
Grymeret al found a highl y significant correlation between the minimal nasal cross-sectional area on aco ustic rhino me try and the Postn as al drip subjec tive fee ling of nasa l patency as reported by pat ients. I I Quantification of nasal cross-sectional areas on acoustic rhi nometry is indepe ndent of airflow. Rhinometry is also minima lly invasive and is particu larly useful for performing repeat measurements in rap id Sn eezing succession. Therefore, we considered it to be a reaso nab le objective test to quantitatively meas ure changes in nasa l congestion.
Our resu lts show that loratadine/pseudoephedrine treatment increased nasal crosssect ional area and nasal volume, whereas the effects of place bo were inconsistent, with a slight decrease in the mea n CSA I, CSA2, and nasa l volume measurements and a very slig ht mean increase in the CSA3 measurement. Loratadine/pseudoephedrine treatment resulted in a positive trend in each aco ustic rhi nome try do main . The fac t that the degree of improvement did not reac h stat istical significance is most likely the res ult of the small number of patien ts for whom we had complete acoustic rhinometry data.
We also used endoscopic inferior tur binate photography because some researchers have fo und that it is a va luable tool for study ing nasal patency objectively.' >!' Our results show that loratadine/pseudoephedrine treatment allev iated redness and edema in the inferior turbinates, decreased the amo unt of nasa l secretions, and improved the overall appearance of the nose . Treatment with placebo was associated with an increase in redness and secretions. T he decreases in inferior turbinate edema and secretions following loratadine/pseudoephedrine treatment were statistically significant, as was the overall In clinical trials. commonly reported adverse events with RHI OCORT AOUA versus vehicle placebo were epistaxis (8%vs 5%). pharyngitis (4%vs 3%). bronchospasm (2%vs 1%). coughing (2%vs <1 %) . and nasal irritation (2%vs <1 %). The overall incidence of adverse events with RHINOCORT AOUA was similar to that observed with vehicle placebo. CONTRAINDICATIONS Hypersen sitivity to any of theingredients in thispreparation contrai ndicates the useofRHINOCORTAQUANasalSpray.
WARNINGS The replacem ent of a systemic cort icosteroid witha topical cort icosteroid can be accompanied by signs of adrenal insufficiency, and in addition some pat ients may experience symptoms of corticosteroid withdrawal, eg, joint and/or muscul ar pai n, lassi tude and depr ession. Pati ents previously treatedforprol onged peri odswith systemic corticosteroi dsandtransferredtotopical corticosteroidsshould be carefu lly monitored for acute ad renal insufficiency in response to stress. In those patients who have asthma or other clinical con ditions requiring long-term system ic cort icosteroid treatment, too rapid a decreasein systemic corticosteroidsmay cause a severe exacerbati on ofthei r symptoms. Patientswhoare ondrugs which suppress the immunesystem are more susceptible to infecti ons thanheal thy individuals. Chicke n pox and measles, forexample, can haveamoreserious or evenfatal coursein non-immunechildren or adultsonimmunosuppressant dosesofcorticosteroids. Insuch childre noradult s, who havenot hadthese diseases, part icul arcareshouldbetakentoavoid exposure. Howthedose, routeanddurationof corticosteroid administrat ion affects therisk of developinga disseminated infection is not known. The contribution of the underl yingdisease and/or prior cort icosteroid treatment to the riskis also not known. If exposed to chicken pox, prophylaxis with var icella zoster immune globulin (VZIG) may be indicated. If expose d to measles, prophyl axis with pooled intramuscul ar immunoglobulin (IG)may be indicat ed. (See the respective package insert s for complete VZIGand IGpresc ribinginformation). If chicken pox devel ops,treatment with antiviral agents may be considered.
PRECAUTIONS: General: Intranasal cort icosteroids may cause a reduction in growth velocity when administered to pedi atric pati ent s (see PRECAUTIONS, Pediatric Use). Rarely, immediate and/or delayed hypersensitivity reactions may occur afterthe intranasal administratio n of budesonide. Rare instances of wheezing, nasal septum perforation, and increased intraocul ar press ure have been repo rted foll owing the intranasal applicationof corticosteroids, including bu desonide. Although system iceffects havebeen minimal wi th recommended doses of RHIN OCORT AQUA NasalSpray, any such effect is dose depend ent. Therefore, largerthanrecommended doses of RH INOCORT AQUA NasalSpray shoul d beavoidedand theminimal effective doseforthe patient should be used(see DO SAGE and ADM INISTRATION). Whenused at largerdoses, systemiccort icosteroid effects such ashypercorticism and adrenalsuppressionmay appear.If such changes occ ur, the dosage ofRHINOCORT AQUA NasalSpray shouldbe di scontinued slowly consistent withaccepted procedures for discontinuing oral corticosteroid therapy. In clin ical studieswith budesonide administered intranasall y, the devel opment of localized infections of the nose and pharynx with Candida albicans has occurred only rarely. Whensuch an infection develops, it may require treatment wi th appropriate local or systemic therapy and discontinuation of treatment with RHINO CORT AQUA Nasal Spray. Pati ents using RHI NOCORT AQUA Nasal Spray overseveral months or longer should beexamined peri odicall y forevidence of Candidainfection or othe r si gnsof adverse effects on the nasal mucosa. RHINOCORT AQ UA NasalSpray should be used with caution, if at all, in patients with act ive or qui escent tuberculous infection, untr eated fungal , bacterial,or systemicviral inf ections,orocular herpessimplex. Becauseof theinhibi toryeffect ofcorticosteroidsonwoundhealing, patientswho haveexperienced recent nasal septal ul cers,nasal surgery, or nasal trauma should not use a nasal corticosteroid until healing has occurred. Hepatic dysfunctioninfluences the pharmacokineti cs ofbudesonid e, similartotheeffect onother cort icosteroids,witha reduced elimina tion rate andincreased systemic availability (see CLINICALPHARMACOLOGY, Special Popul ati ons). Information for Patients: PatientsbeingtreatedwithRHINOCORT AQUA Nasal Spray should receivethefoll owi nginformation andinstructions. Patientswhoareonimmunosuppressant doses of corticoste roidsshouldbewarnedtoavoid exposure to chicken pox or measles and, if exposed, to obtain medi cal advice. Pati ents should use RHINOCORT AQUA Nasal Spray at regular intervals since its eftectiveness depen ds on its regularuse(see OOSAGEand ADMINISTRATION). An improvement in nasal symptomsmay beseenwithinthefirst 24hours after initiation of treatment. Maximum benefit is generallynotachieved unt il 2 weeksafter initi ationof treatment.lnitialassessment forresponseshould bemade duringthistimeframeand periodicallyuntil the patient' s symptoms are stabilized. The patient should take the medication as directed and should not exceed the prescribed dosag e. Th epafient should contact the physician if symptoms do not improveafter twowee ks, or if the conditi on worsens. Patients who experience recurrent episodes of epistaxis (nosebleeds) or nasal septumdiscomfort while takingthis medicati onshouldcontacttheir physician. Forproperuseofthis unitand to attain maximumimprovement, the patient should read and followthe accompanyingpatient instructi ons carefully. It is important to shake thebott lewe ll beforeeach use. The RHIN OCORT AQUA NasalSpray 32mcg bottleshoul d bediscarded after 60 sprays after init ial primi ng, since theamount of bud esonid edeli veredper spray the reafter may be substantially lessthanthe labeled dose. 00 nottransfer anyremaining suspensionto an otherbottle.Drug Interactions: The mainroute of met ab ol ismof budesoni de,aswe ll asother corticosteroids, is vi a cytochromeP4503A (CYP3A). Aft er oraladminist ration of ketoconazo le,a potent inhibitorof cytoch rome P4503A, the mean plasma concentration of orally administered budesonide increased by more than seven fold. Concomitant administration of other known inhibitors of CYP3A (eg, itraconazole, ciarithromycin, erythromycin, etc.) may inhibit the metaboli sm of, and increase the systemic exposure to, budesonide (see WARNINGS, PRECAUTION S, General). Om eprazole, aninhibi tor of cytochrome P450 2C19, did not have effects on the pharmacokineticsof oral bu desonide, whilecimetidine, primarily an inhibi tor of cytochro me P450 lA2, caused a slight decrease in bud esoni de clearance and corres ponding increase in its oral bioavailability. Carcinogenesis, Mutagenesis , Impairment of Fertility: In a two-year study in Sprague-Oawley rats,bu desonidecaused a statisticallysignificant increaseinthe inciden ceof gli omas in the male rats receiving an oral dose of 50 mcglkg (approximately twice the maximum recom mended daily intranasaldose inadults and children onamcg/m' basi s). Notumori genici tywasseeninmaleandfemalerats at respectiveoral doses upto25and 50 mcg/kg (approximatelyequal to andtwo timesthemaximum recommended dai ly intranasal dose in adults and children on a mcg/m' basi s, respectivel y). In two addi tional two-yearstudies in maleFischer and Sprag ue-Dawleyrats, budesonid eca used no gli omasat an oraldose of 50 mcglkg (approximatelytwi cethema ximumrecommended dailyintranasaldose inadultsandchildrenona mcg/m' basi s). However , in male Sprague-Oawley rats, budesonid ecaused astatisticallysignificant increase in the incidence of hepatocell ulartumors at an oral dose of 50 mcg/kg (approximately twice the maximum recommendeddailyintranasaldose inadultsand child renonamcg/m' basis). Theconcurre ntreferencecorticosteroids (prednisoloneand triam cinolone acetoni de) in these two studies showed similar findings. In a 91-week study in mice, budesonide ca used no treatme nt-related carcinogenicity af oral doses up to 200 mcglkg (approximately 3 times themaximumrecomm endeddaily intranasaldose inadults andchildren onamcg/m' basis). Budesonidewas not mutagenic or clastoge nicinsixdi fferent test systems: Ames, salmonella/microsome pl atetest, mouse micronucl eu stest, mouse lymphomatest , chro mosome aberrationtest in human lymph ocytes,sex-linked recessive lethaltest in Drosophila melanogaster, andDNA repair analysisinrat hematocyte culture. Inrat s, bu desonidecausedadecrease inprenatalviabi lityandviability of the pupsatbirth andduring lactati on,al ongwithadecrease inmaternal body-weight gain,atsubcutaneousdoses of 20 mcglkg andabove (less than themaximum recommendeddail y intranasaldoseinadul tsonamcg/m' basis). Nosuch eftects were noted at 5 mcglkg (less thanthe ma ximumrecommended daily intranasal dose in adults on a mcg/m' basis). Pregnancy: Teratogenic Effects: Pregnancy Calegory C-Bud esonide was teratoge nic and embryocidal in rabbits and rats. Budesonideproduced fetal loss, decreased pup weig hts, and skeletal abnormalities atsubcutaneous doses of25mcglkg in rabbitsand 500 mcglkg in rats(approximately 2and 16times themaximumrecommended daily intranasal dose in adults on a mcg/m' basi s). Inanother study in rats, no teratogenicor embryocidal effects we reseenatinhalationdoses upto250mcglkg (approximatelyBtimes the maximumrecomm en ded dailyintranasaldoseinadults onamcg/m' basis).Therearenoadequa teandwellcontrolledstudies in pregnantwomen. RHIN OC ORT AQUA Nasal Spray should beused dur ingpregnancy only if thepotential ben efit justifies the potential risk to thefet us. Experi encewith oral corticosteroidssince their introductionin pharmacologic, asopposed to physiol ogic, doses suggests that rodents are more proneto teratogeniceffectsfromcorticosteroi dsthanhumans.Inaddi tion, because thereis anaturalincreaseincorticosteroid production dur ing pregnancy, mostwomen will requirea lower exogenous corticosteroi d doseand many will notneed corticosteroi d treatmentduring pregnancy. Nanteratagenic Ellects-Hypoadr enalism may occur ininfantsbornof mothers receivingcorticostero idsduring pregnancy. Asimilar adverse event profilewas observed inthe subgrou pof pediatri c patient s 6to12yearsofage. Twoto three percent (2-3%) of patients in clinical trial s discontinued because of adverse events. Systemic corticosteroidside-effects were not reported during controlled clinical studies wi th RHINOCORT AQUA Nasal Spray. If recommended doses areexceede d,however , or if individual sareparticul arly sensitive, symptomsof hypercorticism, ie,Cushing'sSyndrome,couldoccur.Rareadverse eventsreportedfrom post-marketing experience include: nasal septum perf oration, pharynx di sorders (throat irritation, throat pain, swollen throat, burning throat , an d itchy throat), angioedema, anosmia,and palpi tations. Cases of growth suppressio n have been reported for intranasal corticosteroids including RHINOCORT AQUA Nasal Spray (see PRECAUTIONS, PediatricUse).
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determined by Ju niper et al to be a change Table 5 . Visual analog scale scores for eye symptoms greater than approximately 0.5. 9 App lying this form ula to our results, we found that treatment with loratadine/pseudoephedrine was associated wit h an improvement in nasal Itchiness and eye symptoms, both of which were clinically important. The improvement in nasal symptoms was also statistically significant, whi le the improvement in eye symptoms and in the total quality-of-life questionnaire score approached significance. The res ults of visual ana log testing were inconsistent. Visual analog sca le scores indicated that loratadine/pseudoephedrine treatment allevi ated nasa l stuffi ness, nasa l and throat itchiness , and sneezing, but worsened rhinorr hea and postnasa l drip. All eye symp -S oreness or redness BA tom s imp rove d with both active trea tmen t and placebo, and there was no sign ifican t diffe rence in eye results. A number of invest igators have found visu al analog sca les to be unreliable in subj ectively assessing nasa l conges-Swelling tion. Indeed , a seve n-po int Likert scale, such as that used in the rhinoconj unctivitis qualityof-life ques tionnaire, has bee n found to be easier to adm inister and interpret in terms of how much cha nge co nstit utes an MID. t 6 In co nclusio n, there was a goo d correlation between symptom improvement and the findings seen on acoustic rhinometry, endoscopic inferior turbinate pho tography, and the quality-of-life questionn aire, but not with visual ana log sco res. We find that once-a-day fixe dcombination loratadine/pseudoephedrine is effective in relieving the nasal co nges tion in patients with seasonal allergic rhini tis.
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